AR132818A1 - Compuestos para la degradación de la cinasa egfr - Google Patents

Compuestos para la degradación de la cinasa egfr

Info

Publication number
AR132818A1
AR132818A1 ARP240101375A ARP240101375A AR132818A1 AR 132818 A1 AR132818 A1 AR 132818A1 AR P240101375 A ARP240101375 A AR P240101375A AR P240101375 A ARP240101375 A AR P240101375A AR 132818 A1 AR132818 A1 AR 132818A1
Authority
AR
Argentina
Prior art keywords
degradation
compounds
egfr kinase
compound
pharmaceutically acceptable
Prior art date
Application number
ARP240101375A
Other languages
English (en)
Inventor
Huaqing Liu
Bailin Lei
Yizhou Zhao
Xinzhu Qi
Guanjun Liu
Zhiwei Wang
Original Assignee
Beigene Switzerland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Switzerland Gmbh filed Critical Beigene Switzerland Gmbh
Publication of AR132818A1 publication Critical patent/AR132818A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto con la fórmula (1). Una composición farmacéutica que comprende un compuesto de cualquiera de las reivindicaciones 1 - 77, o una sal, estereoisómero, tautómero, o profármaco farmacéuticamente aceptable de este, junto con un excipiente farmacéuticamente aceptable.
ARP240101375A 2023-05-31 2024-05-30 Compuestos para la degradación de la cinasa egfr AR132818A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2023097387 2023-05-31
CN2023125498 2023-10-19
CN2024090756 2024-04-30

Publications (1)

Publication Number Publication Date
AR132818A1 true AR132818A1 (es) 2025-07-30

Family

ID=91670399

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101375A AR132818A1 (es) 2023-05-31 2024-05-30 Compuestos para la degradación de la cinasa egfr

Country Status (13)

Country Link
US (1) US20240425523A1 (es)
EP (1) EP4720071A1 (es)
JP (1) JP2026518202A (es)
KR (1) KR20260020383A (es)
CN (1) CN121194978A (es)
AR (1) AR132818A1 (es)
AU (1) AU2024281173A1 (es)
CL (1) CL2025003597A1 (es)
CO (1) CO2025018512A2 (es)
IL (1) IL324672A (es)
MX (1) MX2025013993A (es)
TW (1) TW202448898A (es)
WO (1) WO2024246838A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202602888A (zh) * 2024-04-09 2026-01-16 大陸商海思科醫藥集團股份有限公司 吡唑衍生物及其在醫藥上的應用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001295041A1 (en) 2000-09-08 2002-03-22 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
GB201311910D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel Compounds
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
GB201504314D0 (en) 2015-03-13 2015-04-29 Univ Dundee Small molecules
AU2016232705C1 (en) 2015-03-18 2021-06-17 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
CA2988414C (en) 2015-06-04 2023-09-26 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
EP3319944A4 (en) 2015-07-10 2019-04-24 Arvinas, Inc. MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
CA2988436A1 (en) 2015-07-13 2017-01-19 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
BR112018008918A8 (pt) 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
AU2017253560B2 (en) 2016-04-20 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
WO2017185036A1 (en) 2016-04-22 2017-10-26 Dana Farber Cancer Institute, Inc. Bifunctional molecules for degradation of egfr and methods of use
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
EP3512842B1 (en) 2016-09-15 2024-01-17 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
SI3526202T1 (sl) 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
CN110753693A (zh) 2016-12-23 2020-02-04 阿尔维纳斯运营股份有限公司 Egfr蛋白水解靶向嵌合分子和相关使用方法
CN111491933A (zh) 2017-12-18 2020-08-04 豪夫迈·罗氏有限公司 具有e3泛素连接酶部分的egfr双功能抑制剂
TW201945357A (zh) 2018-02-05 2019-12-01 瑞士商赫孚孟拉羅股份公司 化合物
WO2019183523A1 (en) 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
US12522615B2 (en) * 2019-06-24 2026-01-13 Boehringer Ingelheim International Gmbh Macrocyclic compounds and derivatives as EGFR inhibitors
WO2021011871A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Mertk degraders and uses thereof
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
WO2021023233A1 (zh) 2019-08-05 2021-02-11 上海科技大学 Egfr蛋白降解剂及其抗肿瘤应用
CN114502564A (zh) 2019-09-26 2022-05-13 贝达药业股份有限公司 Egfr抑制剂、组合物及其制备方法
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
CA3161878A1 (en) 2019-12-17 2021-06-24 Matthew M. Weiss Irak degraders and uses thereof
EP4681715A3 (en) 2019-12-20 2026-01-28 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of egfr
AR120800A1 (es) 2019-12-20 2022-03-16 Hoffmann La Roche Derivados de 6,7-dihidro-5h-pirrolo[1,2-c]imidazol como inhibidores de egfr
PH12022551574A1 (en) 2019-12-23 2024-02-26 Blueprint Medicines Corp Egfr inhibitors
JP2023513854A (ja) 2020-02-18 2023-04-03 テーセウス ファーマシューティカルズ, インコーポレイテッド 大環状化合物およびその使用
CN119823124A (zh) 2020-03-05 2025-04-15 C4医药公司 用于brd9的靶向降解的化合物
CA3171776A1 (en) 2020-04-14 2021-10-21 Shansong ZHENG Tricyclic compounds as egfr inhibitors
WO2021216440A1 (en) 2020-04-20 2021-10-28 Tenova Pharmaceuticals Inc. Novel protein kinase inhibitors
WO2023001069A1 (zh) * 2021-07-23 2023-01-26 南京明德新药研发有限公司 大环酰胺类化合物及其应用
WO2023098656A1 (en) 2021-11-30 2023-06-08 Beigene, Ltd. Compounds for the degradation of egfr kinase

Also Published As

Publication number Publication date
IL324672A (en) 2026-01-01
AU2024281173A1 (en) 2025-12-04
US20240425523A1 (en) 2024-12-26
WO2024246838A1 (en) 2024-12-05
CO2025018512A2 (es) 2026-01-13
EP4720071A1 (en) 2026-04-08
JP2026518202A (ja) 2026-06-04
MX2025013993A (es) 2026-01-07
CL2025003597A1 (es) 2026-02-20
CN121194978A (zh) 2025-12-23
TW202448898A (zh) 2024-12-16
KR20260020383A (ko) 2026-02-11

Similar Documents

Publication Publication Date Title
AR132338A1 (es) Inhibidores de ras
MX2021011606A (es) Compuestos dirigidos a prmt5.
CL2023000196A1 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
MX2024010399A (es) Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias
AR132007A1 (es) Compuestos y métodos para modular ras-pi3k
AR134265A1 (es) Heterociclos y usos de los mismos
CO2022008171A2 (es) Derivado tricíclico de dihidroimidazopirimidona, método de preparación del mismo, composición farmacéutica y uso del mismo
CO2024001367A2 (es) Compuestos antivirales
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
AR131639A1 (es) Inhibidores de kif18a y usos de los mismos
UY39799A (es) Compuestos de pirrolil–sulfonamida
AR132764A1 (es) Inhibidores de tyk2 y sus usos
CO2024011857A2 (es) Compuestos de uracilo n3-sustituidos como inhibidores de trpa1
CO2021017202A2 (es) Compuestos tricíclicos
MX2024011951A (es) Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromaticos
MX2023000926A (es) Nuevo derivado de pirazol.
AR128932A1 (es) Inhibidores de bcl-xl
MX2024012471A (es) Inhibidores de cinasas dependientes de ciclina 9 (cdk9)
MX2024012470A (es) Inhibidores de cinasas dependientes de ciclina 9 (cdk9)
AR133240A1 (es) Compuestos, composiciones y métodos
AR129185A1 (es) Compuestos de 6-(pirimidin-4-il)quinolina sustituidos como inhibidores de la cinasa dependiente de ciclina
AR133286A1 (es) Inhibidores ra2s heterocíclicos de igf-1r para el tratamiento de enfermedades
MX2022005415A (es) Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo.
AR127559A1 (es) Compuestos, composiciones y métodos
AR128868A1 (es) Formulaciones de inhibidor de tyk2 y métodos para elaborarlas